Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT06749613

Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD

Led by Attikon Hospital · Updated on 2025-01-07

40

Participants Needed

2

Research Sites

67 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal disorder. The cardinal symptoms include abdominal pain, flatulence, bloating, and changes in bowel habits related to stool frequency and consistency, in the absence of detectable structural and biochemical abnormalities1,2. The prevalence is estimated at 5-10% among different ethnicities3. A low FODMAP diet is the most common dietary intervention with clinically proven benefits in symptom management and quality of life improvement of patients with Irritable Bowel Syndrome (IBS)4. Recently, a dietary digestive enzyme formulation (FODZYME©) claims similar efficacy in symptom management based on an ex-vivo study5. The study aims to examine the clinical efficacy of this formulation in managing IBS symptoms in patients who have previously clinically responded to a low FODMAP diet.

CONDITIONS

Official Title

Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide written informed consent
  • Be available throughout the study period
  • Have IBS diagnosed by Rome IV criteria (IBS-D, IBS-M, IBS-U) and previously responded to Mediterranean Low FODMAP diet with symptom recurrence (IBS-SSS > 175) after one year
  • Include patients from previous study randomized to Mediterranean Low FODMAP diet who could not adhere to the diet
Not Eligible

You will not qualify if you...

  • Did not participate in the previous Mediterranean Low FODMAP diet study
  • Were randomized to the NICE group in the previous study
  • Have IBS-SSS score less than or equal to 175

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Attikon University General Hospital

Chaïdári, Athens, Greece

Actively Recruiting

2

Attikon University General Hospital

Athens, Greece, 12462

Actively Recruiting

Loading map...

Research Team

A

AREZINA KASTI, PhDc

CONTACT

K

Konstantinos Triantafyllou, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here